Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome.
atypical haemolytic uraemic syndrome
eculizumab
infusion interval
infusion time
ravulizumab
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
09
02
2022
received:
01
12
2021
accepted:
21
02
2022
pubmed:
20
3
2022
medline:
28
7
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
The C5 inhibitor eculizumab is the standard of care for treatment of atypical haemolytic uraemic syndrome (aHUS). Ravulizumab, a next-generation C5 inhibitor, was engineered to have a longer terminal half-life than eculizumab. We describe practical benefits of the advanced ravulizumab 100 mg/mL formulation. Use of ravulizumab results in fewer maintenance infusions per year (25%-50%) compared with eculizumab. Maintenance infusion time of ravulizumab 100 mg/mL is 2-4 times shorter than ravulizumab 10 mg/mL in all weight cohorts and approximately half that of eculizumab for patients weighing <40 kg. Ravulizumab 100 mg/mL requires fewer vials annually than eculizumab in most weight cohorts. With ravulizumab 100 mg/mL, patients and caregivers experience fewer infusions per year and decreased annual infusion times, improving infusion experience. Infusion centres can expect corresponding decreases in resource utilization.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ravulizumab
C3VX249T6L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1081-1087Subventions
Organisme : Alexion, AstraZeneca Rare Disease
ID : MA02210
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687. 10.1056/NEJMra0902814
Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. 10.1111/1744-9987.12763
Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31-42. 10.1016/j.molimm.2015.03.246
Dixon BP, Gruppo RA. Atypical hemolytic uremic syndrome. Pediatr Clin North Am. 2018;65(3):509-525. 10.1016/j.pcl.2018.02.003
Alexion Pharmaceuticals I. SOLIRIS prescribing information.
Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021;2021(3):CD012862. 10.1002/14651858.CD012862.pub2
Greenbaum LA, Licht C, Nikolaou V, et al. Functional assessment of fatigue and other patient-reported outcomes in patients enrolled in the global aHUS registry. Kidney Int Rep. 2020;5(8):1161-1171. 10.1016/j.ekir.2020.05.003
Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep. 2019;4(11):1568-1576. 10.1016/j.ekir.2019.07.016
Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ. Global a HUSR. eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4(3):434-446. 10.1016/j.ekir.2018.11.010
Zuber J, Frimat M, Caillard S, et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30(12):2449-2463. 10.1681/ASN.2019040331
Ito S, Hidaka Y, Inoue N, et al. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23(1):112-121. 10.1007/s10157-018-1610-2
Kato H, Miyakawa Y, Hidaka Y, et al. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23(1):65-75. 10.1007/s10157-018-1609-8
Fakhouri F, Delmas Y, Provot F, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis. 2014;63(1):40-48. 10.1053/j.ajkd.2013.07.011
Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256-1264. 10.1038/nbt1344
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. 10.1056/NEJMoa1208981
Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68(1):84-93. 10.1053/j.ajkd.2015.12.034
Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701-711. 10.1016/j.kint.2015.11.026
de Jorge EG, Macor P, Paixão-Cavalcante D, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol. 2011;22(1):137-145. 10.1681/asn.2010050451
Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909. 10.1371/journal.pone.0195909
Alexion Pharmaceuticals I. ULTOMIRIS prescribing information.
Ariceta G, Dixon BP, Kim SH, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;100(1):225-237. 10.1016/j.kint.2020.10.046
Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;97(6):1287-1296. 10.1016/j.kint.2020.01.035
Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021;36(4):889-898. 10.1007/s00467-020-04774-2
Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540-549. 10.1182/blood-2018-09-876805
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530-539. 10.1182/blood-2018-09-876136
Alexion PI. Alexion receives FDA approval for ULTOMIRIS® (ravulizumab-cwvz) for atypical hemolytic uremic syndrome (aHUS). https://ir.alexion.com/news-releases/news-release-details/alexion-receives-fda-approval-ultomirisr-ravulizumab-cwvz. Accessed July 12, 2021.
Alexion PI. Alexion receives FDA approval for new advanced formulation of ULTOMIRIS® (ravulizumab-cwvz) with significantly reduced infusion time. https://ir.alexion.com/news-releases/news-release-details/alexion-receives-fda-approval-new-advanced-formulation. Accessed July 7, 2021.
Röth A, Hill A, Aguzzi R, et al. An interim analysis of a phase 2 study evaluating the efficacy, safety, and pharmacokinetics of intravenous ravulizumab 100 mg/mL formulation in patients with paroxysmal nocturnal hemoglobinuria. presented at: 25th Congress of the European Haematology Association; June 11-14 2020;
Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ. 2022;25(1):249-259. 10.1080/13696998.2022.2027706
Wang Y, Johnston K, Popoff E, et al. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J Med Econ. 2020;23(12):1503-1515. 10.1080/13696998.2020.1831519
Levy ACP, Tomazos I. Ravulizumab reduces productivity losses versus eculizumab for treating atypical hemolytic uremic syndrome: a ‘cost consequence’ analysis in 4 countries. presented at: ISPOR Europe 2020; 2020; Virtual.
Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020;15(9):e0237497. 10.1371/journal.pone.0237497